It is meant to support those foundations, not replace them
Tirzepatide# Tirzepatide is a 39-amino acid synthetic peptide that activates both the GIP receptor (GIPR) and the GLP-1 receptor
PMCID: PMC11859134
The report highlights early metabolic studies, selected clinical trials, and certain double-blind placebo-controlled investigations that examined markers such as: blood sugar regulation insulin sensitivity cholesterol levels impaired glucose tolerance adipose tissue activity fat release and lipolytic activity While these studies generated interest in AOD-9604 as a potential anti-obesity drug candidate , the report stresses that no authority recognizes it as an active treatment for obesity, weight loss, or human use and emphasizes that it remains designated strictly for research use
BPC-157 accelerates healing, reduces inflammation, and supports gut health
This matters because it shows how researchers expand the endpoint set depending on population and protocol: weight endpoints remain central, while glycaemic endpoints are included when the population and study design require them